Participants were enrolled in Medicare Parts A, B, and D for at least 1 year before starting any of the medications examined in this study
Patients who used Zepbound for 36 weeks lost an average of 21%, but then, when switched to a placebo, after 1 year, they had regained 14% of their weight back
By combining multi-omics technologies such as metabolomics, single-cell transcriptomics and spatial omics, we systematically depict the dynamic changes of GSH in different tissues (such as liver, brain, tumor tissue, etc.) and under different disease states (such as normal, inflammatory, cancerous, etc.), and deeply analyze the functional mechanism of GSH in different physiological and pathological backgrounds, providing a more comprehensive theoretical basis for the diagnosis, treatment and prognosis of diseases
Glutatyon, cilt hcrelerinin salkl kalmasna yardmc olur ve cildin tonunu ve dokusunu iyiletirir